EMEA-002472-PIP02-19
Key facts
| Active substance |
genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII (beremagene geperpavec)
|
| Therapeutic area |
Dermatology
|
| Decision number |
P/0227/2019
|
| PIP number |
EMEA-002472-PIP02-19
|
| Pharmaceutical form(s) |
Gel
|
| Condition(s) / indication(s) |
Treatment of dystrophic epidermolysis bullosa
|
| Route(s) of administration |
Topical use
|
| Contact for public enquiries |
Krystal Biotech, Inc.
Tel. +434 409 0176 |
| Decision type |
RP: decision refers to a refusal on a proposed Paediatric Investigation Plan
|